Investor Presentation on the Financial Results of the Company for the quarter ended June 30, 2026.

gaudium® IVF Delivering Motherhood Dreams August 13,2026 BSE Limited National Stock Exchange of India Limited Phiroze Jeejeebhoy Towers, Dalal Exchange Plaza, C-1, Block G, Street, Fort, Bandra Kurla Complex, Bandra (E), Mumbai — 400001, Maharashtra Mumbai — 400051, Maharashtra Scrip Code — 544709 Symbol - GAUDIUMIVF ISIN: INEOP8B01020 ISIN: INEOP8B01020 Dear Sir/Madam, Subject: Investor Presentation on the Financial Results of the Company for the quarter ended June 30, 2026 Pursuant to the Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we enclose herewith the Investor Presentation on highlights of the Financial Results of the Company for the quarter ended June 30, 2026. This disclosure will also be hosted on the website of the Company at www.gaudiumivfcentre.com. Kindly take the information on record. Thanking you, Yours faithfully. For and on behalf of Gaudium IVF and Women Health Limited (Formerly known as Gaudium IVF and Women Health Private Limited) Naveen Kumar Company Secretary and Compliance Officer Membership No.: A69788 Encl.: a/a Gaudium IVF and Women Health Limited (Formerly known as Gaudium IVF and Women Health Pvt. Ltd.) Registered Office : B1/51, Janakpuri, New Delhi- 110058 | Ph: 011-4885 8585 CIN : L85100DL2015PLC278296 Email : info@gaudiumivfcentre.com Website : www.gaudiumivfcentre.com g% GAUDIUM IVF and WOMEN HEALTH LTD. INVESTOR PRESENTATION Q1 FY27 Safe Harbour This document is prepared only for information purpose and do not solicit/recommend/guide for any Investment/Buy-Sell in any financial instrument of Gaudium IVF and Women Health Limited (“Gaudium”) and/or any of its subsidiary company or associate company. Neither Gaudium nor any of its group company/subsidiary Company/ associate company , directors, or employees related person are responsible for any gains/loss arising to any person/body corporate due to any such transaction as stated above. This document may contain certain forward-looking statements. These forward-looking statements can generally be identified by words or phrases such as “aim”, “anticipate”, “believe”, “expect”, “estimate”, “intend”, “objective”, “plan”, “project”, “shall”, “will”, “will continue”, “will pursue” or other words or phrases of similar meaning. Similarly, statements that describe strategies, objectives, plans or goals are also forward-looking statements. Gaudium cannot assure investors that the expectation reflected in these forward-looking statements will prove to be correct. Given these uncertainties, investors are cautioned not to place undue reliance on such forward- looking statements and not to regard such statements as a guarantee of future performance. Table of Contents 01 02 03 04  CompanyataGlance  IVFIndustryOverview  Center/HubWiseDetails  FinancialSnapshot  ShareholdingPattern &KeyMarketData  JourneyofGaudiumIVF  GrowthDriversinthe  AIThatMakesthe  Q1FY27StandaloneP&L Industry Difference  CaseStudies  ProcessFlow-IVF  Q1FY27ConsolidatedP&L Treatment  EntryBarriersinIndustry  Infrastructure&Facilities  Awardsand atCenters Recognitions  AI-PoweredEnd-to-End  OurMoat,OurMomentum FertilitySolutions  360°CustomerAcquisition  CSRInitiatives  Pan-IndiaPresence  KeyClinicalHighlights  RapidGrowthStrategy  PatientTestimonials  ServingPatientsAround  StrategicMilestones TheGlobe  BoardOfDirectors ABOUT US Company at a Glance Founded: March 2015 by Dr Manika Khanna and Dr. Peeyush Khanna Network: 8 Hubs + 28 Spokes | Presence: 9 States across India Services Revenue Split AI Initiatives to help improve success rate: SiD & ERICA 29.41% 4.35% Success Rates: Success Rates: 62% 85% First Attempt - Multiple Attempts - 66.24% No of OPU: 367 Average Revenue Per Patient: Rs. 3.5 lakhs IVFTreatment Hospital Pharmacy Journey of Gaudium IVF 2009 2016 2017 2019 Janakpuri Greater Ludhiana Patna Hub Hub Kailash Hub Hub SpokesatBihar, Srinagar&Punjab 2026 2024 2023 2022 BSE & NSE Listing Srinagar Hub Bangalore Hub Mumbai Hub South Delhi Hub SpokesatMumbai Gurgaon&Nagpur (Underconstruction Stage) Process Flow - IVF Treatment A seamless, patient-centric journey supported by clinical excellence and care at every step 1 ConversionofLead 2 IVFProcessStarts 3 Hospital&PostCare Injections Success/ LeadGenerated Packageamounteither FailureofET &Followup paidinfullorininstallment asperthepaymentterms (Capturedinpatientfile) DeliveryPackage IfNegative IfPositive (pricingvariesbasis OvumPickUp(OPU) roomcategory. ~70%ofthepackage amountiscollectedbyOPU LeadRe-engaged PatientWalk-in SubsequentThaw ET-Separate RoutineSupport(from Successful package month4-9,including RegistrationofPatient, vaccinesetc) Insemination& FreeOPDandUltrasound EmbryoFormation Incaseof IfInterested miscarriage Supportavailableonlyat DelhiJanakpuriCentre Discussionwithfinance IVF counseloronpackage Embryo Successful FreezeAll Transfer(ET) andpaymentterms AI-Powered End-to-End Fertility Solutions Advanced IVF Male Infertility Ovulation Induction Egg Freezing ERICA SiD Treatment Infertility Surgeries Frozen Embryo Embryo Freezing Gynae Laparoscopy for PCOD/PCOS Transfer Consultation Infertility Key Clinical Highlights SOP-Driven Organization AI-Powered IVF In-House Trained Talent From clinical, embryology and doctors to First in India, 2nd outside the US to Clinicians and embryologists trained within housekeeping. introduce AI tools SID & ERICA. Gaudium. Signature Labs & IVF MANTRANA Constant Innovation State-of-the-art Gaudium Signature Dedicated emotional counselling support Especially for patients with multiple failed IVFs. laboratories and IVF. for patients. ART Law Compliance Global Patient Base Strict adherence to the ART (Regulation) Act. Successfully treated patients from 30+ countries. Success rate at one attempt; early results show an 8–9% increase with SID & ERICA. Strategic Milestones India's First India's No. 1 IVF company to be listed on the stock IVF Clinic ranking as per the Health Survey market, marking a historic milestone in the conducted by Times of India. fertility care industry. India's First India's First IVF chain to introduce Artificial Intelligence in IVF company to receive the European Quality infertility treatment. Award for the highest quality standard. BUSINESS OVERVIEW IVF Industry Overview Strong demographic tailwinds, significant treatment gap and evolving industry structure create a long runway for scalable growth MARKET SIZE & GROWTH SIGNIFICANT UNDERPENETRATION STRUCTURAL SUPPLY GAP IndiaIVFMarketSize(USDBillion) Hugegapbetweenneedandtreatment IVFaccessremains 4.54 concentratedin Top 8 Metro cities DelhiNCR,Mumbai, 1.32 13.1% Ahmedabad,Chennai, CAGR ~27.5 Mn ~300,000 Kolkata,Hyderabad, Infertilecouples IVFcycles Bengaluru,Pune inIndia annually 2024 2034E GlobalIVFmarketprojectedtogrowfrom Industrytransitioningfrom USD27.49BntoUSD54.60Bnat~7.1%CAGR fragmented standalone clinics Indicates <2% toorganizedplatforms India’sshareintheglobalIVFmarket penetrationof expectedtoincreasefrom~4.8%to~8.3% addressabledemand Regulatorytightening(ARTAct) Indiaremainsamongthefastest-growingIVF Only~1 in 50 coupleswhorequire acceleratingshifttowards marketsglobally,outpacingdevelopedmarkets IVFcurrentlyaccesstreatment compliant,scalableplayers Sources:GaudiumIVFRHP,InfomericsAnalytics&ResearchReports Growth Drivers in the Industry IMPROVING DECLINING DELAYED LIFESTYLE & TECHNOLOGY- MEDICAL TOURISM REGULATORY AWARENESS & FERTILITY RATES PARENTHOOD HEALTH FACTORS DRIVEN OUTCOMES ADVANTAGE TAILWIND ACCEPTANCE • India’sfertilityrate • Risingageat • Risingincidenceof • Growingawareness • Advancementsin • IVFtreatmentin • ARTActdriving hasfallenbelow marriageandfirst PCOS,obesity, andreducedstigma AI-enabledembryo Indiacosts standardization, replacementlevels, childbirth, stress,and aroundIVF selection,genetic ~70–80%lower transparency,and indicatingstructural particularlyin hormonaldisorders treatment testing,and thandeveloped compliance demand [Showing first 8,000 characters — download PDF for full document]